Pharming Group N.V.
LSE:0QCO Voorraadrapport
Marktkapitalisatie: €491.5m
Pharming Group Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6 Pharming Group heeft een totaal eigen vermogen van $225.8M en een totale schuld van $95.4M, wat de schuld-eigenvermogensverhouding op 42.3% brengt. De totale activa en totale passiva bedragen respectievelijk $425.5M en $199.7M.
Belangrijke informatie
42.3%
Verhouding schuld/eigen vermogen
Rente dekkingsratio n/a Contant US$171.77m Aandelen US$225.79m Totaal verplichtingen US$199.72m Totaal activa US$425.51m
Recente financiële gezondheidsupdates
Toon alle updates
Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023) Oct 24
Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation Oct 10
Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023) Aug 02
Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union Jun 02
Insufficient new directors Jun 01
Pharming Group N.V. Provides Revenue Guidance for 2024 May 09
First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023) May 08 Pharming Group N.V. announced that it expects to receive €100 million in funding Apr 20
Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022) Mar 15 Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024
Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024 Dec 19
New minor risk - Shareholder dilution Oct 30
Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022) Oct 27
Pharming Group N.V. Appoints Richard Peters as Non-Executive Director Sep 26
Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan Aug 09
First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022) Aug 03
Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer Aug 03
Now 20% undervalued Aug 03
Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor May 18
Investor sentiment improves as stock rises 15% May 10
Investor sentiment improves as stock rises 26% Mar 27
Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021) Mar 17
Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe Feb 18
Now 20% undervalued Feb 10
Now 22% undervalued Jan 24
Investor sentiment improved over the past week Jan 17
Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition Dec 15 Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023
Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib Dec 08
High number of new directors Nov 16
Investor sentiment improved over the past week Nov 03
Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib Oct 29
Third quarter 2022 earnings released: EPS: US$0.014 (vs US$0 in 3Q 2021) Oct 27
Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib Oct 11
Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib Sep 28
Investor sentiment improved over the past week Aug 11
Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021) Aug 05
Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency Aug 02
Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS Aug 01
First quarter 2022 earnings released: EPS: US$0.005 (vs US$0.013 in 1Q 2021) May 13
GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM). May 13
High number of new directors Apr 27
Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA Apr 26 GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million. Apr 23
Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting Apr 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 18
Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome Feb 02
Pharming Receives Positive European Medicines Agency Decision on Paediatric Investigation Plan for Leniolisib in Europe Jan 06
Pharming Announces Results from Clinical Trials for the Treatment of COVID-19 with RUCONEST® Sep 15
Second quarter 2021 earnings released: EPS €0.008 (vs €0.016 in 2Q 2020) Aug 10
Pharming Group N.V Announces Completion of Enrolment in Phase II/III Study with Leniolisib for Activated Pi3k Delta Syndrome Jun 24
Independent Non-Executive Director has left the company May 28
Independent Non-Executive Director has left the company May 28
First quarter 2021 earnings released: EPS €0.011 (vs €0.013 in 1Q 2020) May 14
Full year 2020 earnings released: EPS €0.052 (vs €0.058 in FY 2019) Apr 12
Executive Director & CEO recently bought €489k worth of stock Mar 30 Pharming Group N.V. to Report Fiscal Year 2020 Final Results on Apr 06, 2021
Full year 2020 earnings released: EPS €0.051 (vs €0.058 in FY 2019) Mar 06
Revenue beats expectations Mar 06 Pharming Group N.V. to Report First Half, 2021 Results on Aug 05, 2021
Investor sentiment deteriorated over the past week Dec 29
Investor sentiment improved over the past week Dec 23
Investor sentiment improved over the past week Dec 19
New 90-day high: €1.21 Dec 16 Pharming Group N.V. Announces Board Appointments
Revenue misses expectations Nov 28
Third quarter 2020 earnings released: EPS €0.011 Nov 28
Market bids up stock over the past week Nov 26
New 90-day high: €1.19 Nov 26
Pharming Group N.V. Announces Management Changes Nov 24
Pharming Group N.V. Appoints Jeroen Wakkerman as Chief Financial Officer, Effective 16 November 2020 Nov 09
Third quarter earnings released Oct 30
Third-quarter earnings released: Revenue misses expectations Oct 30
New 90-day low: €0.91 Oct 22
New 90-day low: €0.94 Sep 22
New 90-day low - €1.14 Jul 22
Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $282.2M ) 0QCO } overtreffen de korte termijn passiva ( $79.8M ).
Langlopende schulden: De kortetermijnactiva 0QCO ( $282.2M ) overtreffen de langetermijnschulden ( $119.9M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 0QCO heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van 0QCO is de afgelopen 5 jaar gedaald van 59.8% naar 42.3%.
Analyse van de cashflow Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: 0QCO heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.
Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of 0QCO voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}